|
Category: pharmaceuticals / chemical synthisis
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Appearance: | colorless crystals (est) |
| Assay: | 95.00 to 100.00 %
|
| Food Chemicals Codex Listed: | No |
| Melting Point: | 212.50 °C. @ 760.00 mm Hg
|
| Boiling Point: | 545.68 °C. @ 760.00 mm Hg (est)
|
| Flash Point: | 543.00 °F. TCC ( 283.80 °C. ) (est)
|
| logP (o/w): | -1.808 (est) |
| Soluble in: |
| | water, 1.757e+005 mg/L @ 25 °C (est) |
Organoleptic Properties:
| |
| Odor and/or flavor descriptions from others (if found). |
| |
| |
Cosmetic Information:
Suppliers:
Safety Information:
| Preferred SDS: View |
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
intravenous-child TDLo 33200 ug/kg/24 BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) Cancer Vol. 42, Pg. 53, 1978.
intravenous-human TDLo 17241 mg/kg/6D SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" Annals of Internal Medicine. Vol. 102, Pg. 556, 1985.
intravenous-man LDLo 1536 mg/kg/43W PERIPHERAL NERVE AND SENSATION: FASCICULATIONS
BEHAVIORAL: ATAXIA Drug Intelligence and Clinical Pharmacy. Vol. 21, Pg. 177, 1987.
intravenous-man TDLo 23500 ug/kg/7D SENSE ORGANS AND SPECIAL SENSES: CONJUNCTIVE IRRITATION: EYE
SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE
SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE American Journal of Ophthalmology. Vol. 113, Pg. 587, 1992.
intravenous-man TDLo 649 mg/kg/4D-I PERIPHERAL NERVE AND SENSATION: FASCICULATIONS Drug Intelligence and Clinical Pharmacy. Vol. 21, Pg. 177, 1987.
intraperitoneal-mouse LD50 3779 mg/kg Cancer Research. Vol. 39, Pg. 2204, 1979.
intravenous-mouse LD50 > 7000 mg/kg Drugs in Japan Vol. 6, Pg. 321, 1982.
oral-mouse LD50 3150 mg/kg Drugs in Japan Vol. 6, Pg. 321, 1982.
intraperitoneal-rat LD50 > 5000 mg/kg Drugs in Japan Vol. 6, Pg. 321, 1982.
intravenous-rat LD50 > 5000 mg/kg Drugs in Japan Vol. 6, Pg. 321, 1982.
oral-rat LD50 > 5000 mg/kg Drugs in Japan Vol. 6, Pg. 321, 1982.
|
| Dermal Toxicity: |
subcutaneous-man TDLo 60 mg/kg/90W-I BLOOD: CHANGES IN SPLEEN
SENSE ORGANS AND SPECIAL SENSES: CHANGE IN ACUITY: EAR
BEHAVIORAL: ATAXIA Drug Intelligence and Clinical Pharmacy. Vol. 21, Pg. 798, 1987.
subcutaneous-mouse LD50 > 10000 mg/kg Drugs in Japan Vol. 6, Pg. 321, 1982.
subcutaneous-rat LD50 > 5000 mg/kg Drugs in Japan Vol. 6, Pg. 321, 1982.
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | pharmaceuticals / chemical synthisis |
| Recommendation for cytarabine usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for cytarabine flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
References:
| | 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one |
| NIST Chemistry WebBook: | Search Inchi |
| Pubchem (cid): | 6253 |
| Pubchem (sid): | 134975262 |
Other Information:
| (IUPAC): | Atomic Weights of the Elements 2011 (pdf) |
| Videos: | The Periodic Table of Videos |
| tgsc: | Atomic Weights use for this web site |
| (IUPAC): | Periodic Table of the Elements |
| CHEBI: | View |
| CHEMBL: | View |
| KEGG (GenomeNet): | C02961 |
| HMDB (The Human Metabolome Database): | HMDB15122 |
| FooDB: | FDB001979 |
| MedlinePlusSupp: | View |
| VCF-Online: | VCF Volatile Compounds in Food |
| ChemSpider: | View |
| Wikipedia: | View |
| EFSA Update of results on the monitoring of furan levels in food: | Read Report |
| EFSA Previous report: Results on the monitoring of furan levels in food: | Read Report |
| EFSA Report of the CONTAM Panel on provisional findings on furan in food: | Read Report |
Formulations/Preparations: depocyt is available in 5 ml, ready-to-use, single-use vials containing 50 mg of cytarabine. depocyt is formulated as a sterile, nonpyrogenic, white to off-white suspension of cytarabine in sodium chloride 0.9% wv in water for injection. depocyt is preservative-free. cytarabine, the active ingredient, is present at a concentration of 10 mgml and is encapsulated in the particles. inactive ingredients at their respective approximate concentrations are cholesterol, 4.1 mgml; triolein, 1.2 mgml; dioleoylphosphatidylcholine (dopc), 5.7 mgml; and dipalmitoylphosphatidylglycerol (dppg), 1.0 mgml. the ph of the product falls within the range from 5.5 to 8.5. cytarabine liposome injection
|
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| 4- | amino-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one | | 4- | amino-1-(b-D-arabinofuranosyl)-2(1H)-pyrimidinone | | 4- | amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one | | 4- | amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one | | 4- | amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-2(1H)-pyrimidinone | | 4- | amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxyméthyl)tétrahydrofuran-2-yl]pyrimidin-2(1H)-one | | 4- | amino-1-b-D-arabinofuranosyl-2(1H)-pyrimidinone | | | arabinocytosine | | 1-b-D- | arabinofuranosyl-4-amino-2(1H)pyrimidinone | | 1-(b-D- | arabinofuranosyl)cytosine | | 1- | arabinofuranosylcytosine | | 1-b-D- | arabinofuranosylcytosine | | | arabinoside C | | | arabinosylcytosine | | 1-b-D- | arabinosylcytosine | | | arafcyt | | | cytarabin | | | cytarabinoside | | | cytarabinum | | | cytarbel | | b- | cytosine arabinoside | | | cytosine b-D-arabinofuranoside | | | cytosine b-D-arabinoside | | | cytosine-1-b-arabinofuranoside | | | cytosine-1-b-D-arabinofuranoside | | | depocyte | | | erpalfa | | | spongocytidine | | | tarabine |
Articles:
|